Pathology & Oncology Research

, Volume 3, Issue 2, pp 126–129

Serum Levels of IL-lβ, IL-6, TNF-α, sTNF-RI and CRP in Patients with oral cavity cancer

  • Ewa Jablonska
  • Leszek Piotrowski
  • Zyta Grabowska
Article

Abstract

Pro-inflammatory cytokines, such as interleukin-lβ (IL-lβ), interleukin-6 (IL-6) and tumor necrosis factor- (TNF-α) play an essential role in the regulation of immune response to, and may have prognostic significance in, cancer. The aim of this study was to examine the relationship between the serum levels of IL-lβ, IL-6 and TNF-α as well as the concentrations of soluble TNF receptor I (sTNF-RI) and C-reactive protein (CRP) in patients with squamous cell carcinoma of oral cavity. Results obtained were confronted with squamous cell carcinoma antigen (SCO concentrations. IL-lβ IL-6 and TNF-α serum levels as well as sTNF-RI and CRP concentrations were higher in patients than in controls. The increased serum levels appeared to be related to the clinical stage of disease. There was a correlation between IL-lβ and sTNF-RI. IL-6 and IL-lβ correlated with CRP levels. The mean concentrations of SCC were also elevated. IL-6 and sTNF-RI seemed to be the most sensitive parameters in early stages and may be used as additional markers in oral cancer

Key words

oral cancer IL-1β IL-6 TNF-α sTNF-RI CRP SCC 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cordingely FT, Blanchi A, Hoffbrandt AA et al: Tumor necrosis factor as an autocrine tumor growth factor for chronic B cell malignancies. Lancet i: 969–973, 1988.CrossRefGoogle Scholar
  2. 2.
    Deehan DD, Heys SD, Simpson WG et al: In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br J Cancer 69:1130–1135,1994.PubMedGoogle Scholar
  3. 3.
    Gallo O;Gori A M, Attanasio M et al: Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer. Br J Cancer 68:465–468; 1993.PubMedGoogle Scholar
  4. 4.
    Kishimoto T, Akira S, Narazaki M et al: Interleukin-6 family of cytokines and gp 130. Blood 86:1243–1254:1995.PubMedGoogle Scholar
  5. 5.
    Morinaga Y, Suzuki H, Takatsuki F et al: Contribution of IL-6 to the antiproliferative effect of IL- lb and tumor necrosis factor on tumor cell lines. J Immnunol 143:3538–3542, 1989.Google Scholar
  6. 6.
    Aderka D, Junrning LE, Vilcek J: IL-6 inhibits lipopolysaccha-ride-induced tumor necrosis factor production in cultured human monocytes, U937, and in mice. J Immunol 143:3517–3523,1989.PubMedGoogle Scholar
  7. 7.
    McGee DW, Bamberg T, Vitkus SJD et al: A synergistic relationship between TNF-a, IL-1b, and TGF-bl on IL-6 secretion by the IEC-6 intestinal epithelial cell line. Immunology 86:6–11, 1995.PubMedGoogle Scholar
  8. 8.
    Schindler R, Mancilla J, Endress S et al: Correlations and interactions in the production of interleukin-6 (IL-6); IL-lb; and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF Blood 75:40–47, 1990.PubMedGoogle Scholar
  9. 9.
    Dinarello CA: Interleukin-1 in disease. Kejo J Med; 43:131–136, 1994.Google Scholar
  10. 10.
    Belldegrun A, Pierce W, Sayah D et al: Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with IL-2-based immunotherapy. J Immunother 13:175–180, 1993.CrossRefGoogle Scholar
  11. 11.
    Grosen EA, Granger G A, Gatanga M et al: Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy. Gynecol Oncol 50:68–77, 1993.PubMedCrossRefGoogle Scholar
  12. 12.
    Schroder W, Ruppert C, Bender HG: Concomitant measurements of interleukin-6 (IL-6) in serum and peritoneal fluid of patients with benign and malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol 56:43–46, 1994PubMedCrossRefGoogle Scholar
  13. 13.
    Yanagawa H, Sone S, Takahashi Y et al: Serum levels of interleukin 6 in patients wíth lung cancer. Br J Cancer 71:1095–1098, 1995PubMedGoogle Scholar
  14. 14.
    Gallo O;Gari AM, Attanasio M et al: Interleukin-6 serum level and monocyte production in head and neck cancer. Brit J Cancer 65:479–480, 1992.PubMedGoogle Scholar
  15. 15.
    Gehr G, Gentz R, Brockhaus M et al: Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J Immunol 149:911–917, 1992.PubMedGoogle Scholar
  16. 16.
    Vitolo D, Palmieri MB, Ruco LP et al: Cytokine production and expression of adhesion molecules and integrins in tumor infiltrating lymphomononuclear cells of non-small cell carcinomas of the lung. Am J Pathol 145:322–329, 1994.PubMedGoogle Scholar
  17. 17.
    Tartour E, Darval T, Mosseri V. et al: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy, and poor survival in melanoma patients. Br J Cancer 69:911–913, 1994.PubMedGoogle Scholar
  18. 18.
    Bernelmans MHA, Gouma DJ, Buurman WA: LPS-induced sTNF-receptor release in vivo in a murine model. J Immunol 151:5554–5562,1993.Google Scholar
  19. 19.
    Higuchi M;Aggarwal BB: inhibition of ligand binding and proliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant P60 and P80 receptor. Biochem Biophys Res Commun 181:638–643, 1992.CrossRefGoogle Scholar
  20. 20.
    Zeller JM, Sullivan BL: C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG stimulated monocytes and neutrophils. J Leuk Biol 52:449–455, 1992.Google Scholar
  21. 21.
    Grandis JK, Snyderman CH, Johnsosn JT: Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer. Cancer 70:2166–2171, 1992.PubMedCrossRefGoogle Scholar

Copyright information

© W. B. Saunders & Company Ltd 1997

Authors and Affiliations

  • Ewa Jablonska
    • 1
    • 2
  • Leszek Piotrowski
    • 1
    • 2
  • Zyta Grabowska
    • 1
    • 2
  1. 1.Department of ImmmunopathologyMedical AcademyBialystokPoland
  2. 2.Department of Oral and Maxillofacial SurgeryMedical AcademyBialystokPoland

Personalised recommendations